Sophiris
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Topsalysin
    • Prostate Cancer
    • BPH (benign prostatic hyperplasia)
  • Patients
    • Resources/Advocacy Groups
    • Clinical Trials
  • Publications
  • Investor
    • News
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Contact IR
  • News
  • Contact Us
Credible Science.
Incredible Therapeutics.

Sophiris Bio Inc. (NASDAQ: SPHS) is a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of urological diseases.

read more
+
Credible Science.
Incredible Therapeutics.
+
read more
Topsalysin.

Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.

read more
+
Topsalysin.
+
read more
Phase 2b Localized
Prostate Cancer Study.

Sophiris Bio has reported data from a multi-center, open label, Phase 2b study evaluating the safety and efficacy of targeted intraprostatic administration of topsalysin for the treatment of histologically proven, clinically significant, localized prostate cancer.

read more
+
Phase 2b Localized
Prostate Cancer Study.
+
read more
news.dc

November 7, 2019
Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

October 21, 2019
Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

+
read more
news.
+
read more
© Sophiris Bio Corp. 2019 All rights reserved
  • Terms and Conditions
@sophiris_bio on Linkedin
MENU
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Topsalysin
    • Prostate Cancer
    • BPH (benign prostatic hyperplasia)
  • Patients
    • Resources/Advocacy Groups
    • Clinical Trials
  • Publications
  • Investor
    • News
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Contact IR
  • News
  • Contact Us